HolderBook

Stonepine Capital Management, LLC

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1440771
Reported value
$390.9M
Positions
93
Top 10 weight
45.4%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
EVOLUS INC CALLEOLS$28.4M3,180,3247.26%+3.67pp16q+80.8%+$12.7M
ADMA BIOLOGICS INC CALLADMA$28.3M1,480,0007.24%+0.42pp19q+100.0%+$14.1M
VERASTEM INCVSTM$25.6M6,699,2546.55%-0.46pp8q+102.9%+$13.0M
TENAX THERAPEUTICS INCTENX$19.2M1,320,0004.91%-1.33pp3q+35.4%+$5.0M
NEKTAR THERAPEUTICSNKTR$16.8M241,3084.31%+1.86pp5q+183.9%+$10.9M
ULTRAGENYX PHARMACEUTICAL IN CALLRARE$12.7M50,0003.24%-newNEW
CAMP4 THERAPEUTICS CORPCAMP$12.1M2,779,2443.11%+0.65pp3q+100.0%+$6.1M
ELOXX PHARMACEUTICALS INC$11.7M844,3203.00%-newNEW
AYTU BIOPHARMA INCAYTU$11.6M5,903,1592.96%+2.10pp13q+645.1%+$10.0M
INSMED INC CALLINSM$11.2Moptions only2.87%-newOPTIONS
KAZIA THERAPEUTICS LTDKZIA$9.7M690,3582.49%+1.46pp3q+100.0%+$4.9M
AZITRA INCAZTR$8.9M87,083,0292.27%-newNEW
MEDTRONIC PLC CALLMDT$8.8Moptions only2.24%-newOPTIONS
INDIVIOR PHARMACEUTICALS INCINDV$8.2M200,0002.10%-newNEW
CORBUS PHARMACEUTICALS HLDGSCRBP$8.0M850,0002.04%+0.60pp3q+121.7%+$4.4M
ABBOTT LABORATORIES CALLABT$7.6Moptions only1.94%-newOPTIONS
SATELLOS BIOSCIENCE INCMSLE$7.4M983,2481.91%+1.68pp2q+883.2%+$6.7M
ZEVRA THERAPEUTICS INCZVRA$7.4M517,4021.90%+0.11pp8q+7.8%+$536.3K
ABEONA THERAPEUTICS INCABEO$6.9M1,114,5681.76%+0.24pp5q+49.3%+$2.3M
CNS PHARMACEUTICALS INCCNSP$6.6M1,387,4941.70%+1.64pp3q+2174.6%+$6.3M
BOSTON SCIENTIFIC CORP CALLBSX$6.5Moptions only1.66%-newOPTIONS
EDESA BIOTECH INCEDSA$6.4M912,8781.63%+1.57pp4q+2942.9%+$6.2M
BIOMARIN PHARMACEUTICAL INC CALLBMRN$6.2Moptions only1.60%-newOPTIONS
CABALETTA BIO INCCABA$5.7M1,834,2001.46%+1.41pp3q+3568.4%+$5.5M
AN2 THERAPEUTICS INCANTX$5.3M1,103,3841.37%+0.39pp5q+54.6%+$1.9M
CURIS INCCRISXXXX$4.9M17,624,3721.25%+0.43pp3q+373.0%+$3.8M
SURROZEN INCSRZN$4.7M68,0011.20%+0.82pp9q+106.0%+$2.4M
XILIO THERAPEUTICS INCXLO$4.3M451,9881.11%+0.89pp2q+604.4%+$3.7M
ADICET BIO INCACET$4.2M491,0361.09%+0.48pp3q+121.2%+$2.3M
XERIS BIOPHARMA HOLDINGS INC CALLXERS$4.2Moptions only1.07%+0.33pp2qOPTIONS
TELA BIO INCTELA$4.0M5,324,8541.02%+0.37pp13q+103.5%+$2.0M
HERON THERAPEUTICS INC CALLHRTX$3.4M981,5740.87%+0.11pp7q-30.0%-$1.5M
IN8BIO INCINAB$3.3M2,319,8490.84%+0.44pp5q+249.7%+$2.3M
INHIBIKASE THERAPEUTICS INCIKT$3.2M2,864,7740.81%+0.17pp7q+199.3%+$2.1M
SPRUCE BIOSCIENCES INCSPRB$3.1M57,5900.80%-newNEW
QUOIN PHARMACEUTICALS LTDQNRX$3.0M965,0320.77%+0.63pp3q+1705.1%+$2.8M
SI-BONE INC CALLSIBN$3.0Moptions only0.77%+0.19pp2qOPTIONS
OKYO PHARMA LTDOKYO$2.6M1,725,9920.66%+0.11pp2q+103.1%+$1.3M
NEUMORA THERAPEUTICS INC. CALLNMRA$2.5Moptions only0.64%+0.17pp2qOPTIONS
PASITHEA THERAPEUTICS CORPKTTA$2.3M4,402,9360.58%+0.33pp3q+429.6%+$1.8M
SOL-GEL TECHNOLOGIES LTDSLGL$2.1M28,9380.55%-0.33pp2q+4.2%+$86.0K
PULMONX CORPLUNG$2.1M1,630,8720.54%+0.15pp5q+112.3%+$1.1M
X4 PHARMACEUTICALS INCXFOR$2.1M449,9780.54%-0.02pp4q+34.2%+$535.5K
ARDELYX INC CALLARDX$2.1Moptions only0.54%+0.18pp2qOPTIONS
DELCATH SYS INC CALLDCTH$2.0Moptions only0.51%+0.14pp3qOPTIONS
MOONLAKE IMMUNOTHERAPEUTICSMLTX$1.9M100,0000.50%-newNEW
MAXCYTE INCMXCT$1.8M1,503,2120.47%+0.19pp4q+49.6%+$613.2K
PHATHOM PHARMACEUTICALS INCPHAT$1.8M170,0200.47%+0.25pp2q+240.0%+$1.3M
CYBIN INCHELP$1.8M459,8100.47%+0.21pp3q+243.0%+$1.3M
CALCIMEDICA INCCALC$1.8M2,751,0290.46%-newNEW
CONNECT BIOPHARMA HLDGS LTDCNTB$1.7M728,5080.44%+0.12pp2q+135.0%+$996.0K
ADIAL PHARMACEUTICALS INCADIL$1.6M727,5630.41%-newNEW
ZENTALIS PHARMACEUTICALS INCZNTL$1.6M323,1660.40%+0.15pp6q+20.1%+$262.2K
CYTOMX THERAPEUTICS INCCTMX$1.5M410,0000.39%-0.36pp2q+105.0%+$787.5K
MANNKIND CORP CALLMNKD$1.5Moptions only0.38%-0.12pp4qOPTIONS
NUVECTIS PHARMA INCNVCT$1.5M80,0000.38%-newNEW
RADIOPHARM THERANOSTICS LTD?RADX$1.5M153,000,000?0.37%+0.08pp3q
CRESCENT BIOPHARMA INC.CBIO$1.4M80,0000.37%-0.26pp3q-5.9%-$90.0K
PMV PHARMACEUTICALS INCPMVP$1.4M1,072,1720.37%+0.02pp7q+51.4%+$487.9K
ORUKA THERAPEUTICS INCORKA$1.4M15,0000.37%-newNEW
NERVGEN PHARMA CORPNGEN$1.3M843,3560.33%-newNEW
ONKURE THERAPEUTICS INCOKUR$1.2M261,3680.30%+0.09pp2q+97.1%+$587.3K
ARVINAS INCARVN$997.2K120,0000.26%+0.14pp2q+336.4%+$768.7K
BIOAGE LABS INCBIOA$980.4K40,0000.25%-0.10pp6q-20.0%-$245.1K
SINTX TECHNOLOGIES INCSINT$891.0K836,8200.23%-newNEW
OPUS GENETICS INCIRD$827.9K201,4360.21%+0.09pp2q+193.3%+$545.6K
QT IMAGING HLDGS INCQTI$814.0K200,0000.21%-newNEW
BOUNDLESS BIO INCBOLD$773.0K309,1900.20%-0.07pp5q-48.3%-$721.2K
CELLECTAR BIOSCIENCES INCCLRB$581.3K209,1000.15%-newNEW
EUPRAXIA PHARMACEUTICALS INCEPRX$575.0K86,9820.15%-newNEW
SAB BIOTHERAPEUTICS INCSABS$571.5K146,5420.15%+0.07pp2q+193.1%+$376.5K
ADLAI NORTYE LTDANL$557.9K48,5140.14%-newNEW
SENSEONICS HLDGS INCSENS$553.0K97,3600.14%-newNEW
IMAGENEBIO INCIMA$539.0K96,1720.14%-newNEW
PLIANT THERAPEUTICS INCPLRX$525.6K461,0760.13%+0.02pp4q+105.2%+$269.5K
CODEXIS INCCDXS$495.7K219,3240.13%-0.15pp4q-47.5%-$449.0K
PRECISION OPTICS CORP INC MAPOCI$473.2K92,7800.12%-0.05pp2q-7.2%-$36.8K
UPSTREAM BIO INCUPB$462.7K66,8640.12%-0.01pp2q+91.0%+$220.5K
REIN THERAPEUTICS INCRNTX$453.5K436,0760.12%-newNEW
HUMACYTE INCHUMA$361.0K462,5980.09%-newNEW
MILESTONE SCIENTIFIC INCMLSS$348.6K666,6660.09%-newNEW
KALARIS THERAPEUTICS INCKLRS$245.2K60,2440.06%+0.02pp2q+195.3%+$162.2K
VERRICA PHARMACEUTICALS INCVRCA$241.5K88,4170.06%-0.15pp3q-11.3%-$30.9K
PROCESSA PHARMACEUTICALS INCPCSA$211.2K110,0000.05%flat3q+100.0%+$105.6K
INOVIO PHARMACEUTICALS INCINO$210.2K1,345,2370.05%-newNEW
BIOATLA INCBCAB$136.1K32,8640.03%-newNEW
COMPUGEN LTDCGEN$134.3K62,7740.03%-0.05pp3q-39.8%-$88.9K
PRECISION BIOSCIENCES INCDTIL$128.4K40,0000.03%-newNEW
OVID THERAPEUTICS INCOVID$114.6K42,6000.03%-0.01pp3q+6.5%+$7.0K
EVAXION ASEVAX$108.9K35,1240.03%flat3q+78.2%+$47.8K
TENAYA THERAPEUTICS INCTNYA$107.4K352,0010.03%-newNEW
GRACE THERAPEUTICS INC?GRCE$62.1K294,550?0.02%-new
APREA THERAPEUTICS INCAPRE$0137,1740.00%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 88.0%Medical Devices 7.4%Other sectors 0.3%Not classified 4.3%
 
SectorValueShare
Biotech & Pharma$342.8M88.0%
Medical Devices$28.9M7.4%
Other sectors$1.0M0.3%
Not classified$16.6M4.3%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+8.4%+14.8%-6.4%84%
Q1 2026-11.6%-4.6%-7.0%94%
Q4 2025+8.9%+2.4%+6.5%100%
Q3 2025+17.4%+7.8%+9.6%95%
Q2 2025+4.2%+10.5%-6.2%79%
Q1 2025-8.0%-4.6%-3.5%100%
Q4 2024-4.2%+2.1%-6.3%97%
Q3 2024+41.5%+5.4%+36.0%81%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$390.9M933247121145.4%45
Q1 2026$249.7M722318261574.9%44
Q4 2025$137.0M642912172355.3%44
Q3 2025$123.0M581922161962.1%44
Q2 2025$101.9M582024142859.4%44
Q1 2025$102.8M66231822958.1%44
Q4 2024$123.9M52221316858.9%45
Q3 2024$158.2M3817125469.2%44
Q2 2024$109.6M251248787.3%52
Q1 2024$126.1M20847492.3%45
Q4 2023$231.2M160211795.3%44
Q3 2023$301.0M235132383.9%44
Q2 2023$277.2M21686784.2%42
Q1 2023$298.2M22796486.1%42
Q4 2022$237.7M19666690.7%45
Q3 2022$222.4M19168787.8%41
Q2 2022$214.9M254118774.4%43
Q1 2022$241.1M28898374.6%46
Q4 2021$217.9M2381321683.5%45
Q3 2021$219.8M319147481.3%43
Q2 2021$191.2M2631112679.1%47
Q1 2021$185.1M2914114673.1%44
Q4 2020$130.6M21768381.5%43
Q3 2020$96.1M17637288.7%44
Q2 2020$51.6M133191795.8%44
Q1 2020$94.6M271098659.9%44
Q4 2019$143.5M2371151081.8%44
Q3 2019$103.0M267513676.7%44
Q2 2019$145.2M253128875.3%44
Q1 2019$173.9M301549768.6%44
Q4 2018$113.9M22000077.2%44

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.